Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Laboratoires SMB
Laboratoires SMB
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Pravafenix
Fenofibrate
,
Pravastatin
2011-04-14
2024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Retinol
melanoma
,
carcinoma
,
neoplasms
,
non-small-cell lung carcinoma
,
head and neck neoplasms
,
lung neoplasms
,
respiratory tract diseases
,
germ cell and embryonal neoplasms
,
small cell lung carcinoma
,
lung diseases
,
respiratory tract neoplasms
,
bronchogenic carcinoma
,
thoracic neoplasms
,
adenocarcinoma
,
bronchial diseases
,
neoplasms by histologic type
,
neoplasms by site
,
nerve tissue neoplasms
,
osteoporosis
,
postmenopausal osteoporosis
,
chronic renal insufficiency
,
vitamin d deficiency
,
renal insufficiency
,
kidney transplantation
,
anemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use